Key points are not available for this paper at this time.
TC was noninferior to TP and should be a standard treatment option for metastatic or recurrent cervical cancer. However, cisplatin is still the key drug for patients who have not received platinum agents.
Kitagawa et al. (Tue,) studied this question.